← Signal Board

X4 Pharmaceuticals financial statements

X4 파머슈티컬NASDAQ:XFOR · Nasdaq · Healthcare · sector #20
$2.79-0.71%
2026-10-08 close · prelim

X4 Pharmaceuticals's published financial data is dated 2026-10-04. 2024 revenue was $3M. 2024 operating profit was −$36M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -9.40
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-9.40
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
63.81%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -5119%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-1,423.6%
Interest coverage
-4.2x
Return on equity (ROE)
-169.1%

Operating margin −5pp

Operating loss
Interest coverageBase -4.2x adverse case -4.2x
Return on equity (ROE)Base -169.1% adverse case -204.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -4.2x adverse case -3.5x
Return on equity (ROE)Base -169.1% adverse case -179.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -4.2x adverse case -3.2x
Return on equity (ROE)Base -169.1% adverse case -215.2%

Interest coverage limit

Already below the limit by 1,766.5pp

Interest coverage limit at an operating margin of 342.9%

Interest expense coverage threshold

X4 Pharmaceuticals notifications

Quantus Signal · live data · not investment advice · Privacy Policy